Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

NeoGenomics to buy Genoptix

NeoGenomics, Inc., a provider of cancer-focused genetic testing services, has entered into a definitive agreement to acquire Genoptix, Inc. for $125 million in cash and 1 million shares of NeoGenomics common stock., PE Hub reported. Genoptix is a clinical oncology laboratory, specializing in hematology and solid tumor testing and is backed by Ampersand Capital Partners and 1315 Capital. William Blair and Company advised Genoptix on the transaction.

Tags:

Mergers and Acquisitions,M&A,M&A deals